Rs 4,000-cr IMA scam: CBI books senior IPS officers Hemant Nimbalkar, Ajay Hilori

Bengaluru, Jul 10: Karnataka health minister B Sriramulu on Thursday said that the government is planning to increase number of COVID-19 testing labs and technicians in the state.

Speaking to news agency, Sriramulu said, "We have 72 labs where COVID-19 tests are conducted. They are under pressure with increased number of tests. When lab technicians are quarantined, it gets difficult to complete work. So we are considering to increase number of labs and technicians."

Speaking on the community transmission of COVID-19 in Bengaluru, he said, "The experts are already deliberating over the issue of community transmission. According to me the community spread has not taken place yet."

Meanwhile, Cabinet Minister Madhu Swamy said that the government is calling for foreign investment for which Boston Consulting Group (BCG) has been hired by the state government.

Speaking to the reporters after the Cabinet meeting, Swamy said, "We call for foreign investment in Karnataka for which we need an agency who has to coordinate, who has to bring outsiders in Karnataka to invest in the state. For that we have hired a company by name Boston consulting Group(BCG) we will be paying them Rs 1 crore for twelve months."

Mangaluru, Mar 11: Nitte Education Trust is among the top 50 reputed institutions in the country selected by NITI Aayog for setting up Atal Incubation Centre under Union government's Atal Innovation Mission (AIM) scheme.

NITI Aayog has sanctioned Rs 9 Crore to Nitte Education Trust for setting up a full-fledged Incubation Centre at Nitte, of which Rs 2.5 crores has been received as first instalment according to a press release here on Wednesday.

Atal Incubation Centre- Nitte provides start-ups with valuable guidance, technological aid, access to investors, networking and facilitating a host of other services required for start-ups to survive and scale. Start-ups also receive direction through the robust chain of mentors who give sector-specific information and real-time practical guidance.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.